Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Ventures","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Locate Bio Raises \u00a39.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody Fusion","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Locate Bio"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Product Type
            filter News Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Locate Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Locate Bio Raises £9.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody Fusion

              Details:

              The proceeds will be used to advance the clinical development of Locate Bio's lead product, LDGraft (rhBMP-2), which is currently undergoing evaluation in early-stage clinical trials for treating patients with degenerative disc disease.

              Lead Product(s): rhBMP-2

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: LDGraft

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Mercia Ventures

              Deal Size: $9.8 million Upfront Cash: Undisclosed

              Deal Type: Funding April 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY